Pfeifer, A;Zimmermann, K;Plank, C
Magnetic nanoparticles for biomedical applications.
Pharm Res
2012
29
5
1161-4

Mannell, H;Pircher, J;Fochler, F;Stampnik, Y;Räthel, T;Gleich, B;Plank, C;Mykhaylyk, O;Dahmani, C;Wörnle, M;Ribeiro, A;Pohl, U;Krötz, F
Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles.
Nanomedicine
2012
8
8
1309-18

Luraghi, P;Schelter, F;Kruger, A;Boccaccio, C
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
Front Pharmacol
2012
3
164

Cui, H;Grosso, S;Schelter, F;Mari, B;Kruger, A
On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1?, and miR-210.
Front Pharmacol
2012
3
134

Reinheckel, T;Peters, C;Kruger, A;Türk, B;Vasiljeva, O
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.
Front Pharmacol
2012
3
133

Grismayer, B;Sato, S;Kopitz, C;Ries, C;Soelch, S;Schmitt, M;Baretton, G;Kruger, A;Luther, T;Kotzsch, M;Magdolen, V
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Biol Chem
2012
393
12
1449-55

Grismayer, B;Sölch, S;Seubert, B;Kirchner, T;Schäfer, S;Baretton, G;Schmitt, M;Luther, T;Kruger, A;Kotzsch, M;Magdolen, V
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.
Mol Cancer
2012
11
62

Reckhenrich, AK;Koch, C;Egana, JT;Plank, C
The use of non-viral gene vectors for bioactive poly-(D,L-lactide) implant surfaces in bone tissue engineering.
Eur Cell Mater
2012
23
441-8

Ortner, V;Kaspar, C;Halter, C;Töllner, L;Mykhaylyk, O;Walzer, J;Günzburg, WH;Dangerfield, JA;Hohenadl, C;Czerny, T
Magnetic field-controlled gene expression in encapsulated cells.
J Control Release
2012
158
3
424-32

Schäfer, H;Dieckmann, C;Korniienko, O;Moldenhauer, G;Kiefel, H;Salnikov, A;Kruger, A;Altevogt, P;Sebens, S
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Cancer Lett
2012
319
1
66-82